Ferritin
Material: | 1 ml serum 1 ml plasma (Stability at 4°C – 8°C: 7 days) 0,5 ml CSF (Stability at 4°C: 7 days) |
Methods: | Ligandenassays → Chemilumineszenz-Immunoassay (CLIA) | Reference range | Serum/plasma: Men: 22 µg/l – 275 µg/l Women: 5 µg/l – 204 µg/l Children: Please refer to findings report
CSF: < 10 ng/ml; grey area at 10 – 15 ng/ml, i.e. in case of artificial blood contamination, cell destruction |
Indication | Serum: Differential diagnosis of anemia, diagnosis of iron deficiency, regular checks of oral iron substitution, monitoring of risk groups, tumors, iron overload CSF: Proof of/ruling out of CNS-bleeds, especially older or smaller subarachnoid bleeding; prognosis in case of herpes simplex encephalitis (hemorrhagic necrotizing form) |
Please note | The ferritin circulating in the blood, correlates with the storage iron content of the reticulo-histiocytic system and therefore informs of the reserve iron concentration of the organism, provided that no ferritin from parenchymal cells, such as the liver, is released nor serum ferritin synthesis or catabolism is disturbed. In these situations, the evaluation of the soluble transferrin-receptor in the serum may be helpful. Therapeutically, an iron substitution is recommended in ferritin levels of < 20 µg/l, as iron storage is exhausted.
Please also refer to section “Iron deficiency” (Indications directory) Ferritin is also synthesized in the CNS. An evaluation of CSF/Serum-quotient does not make sense as over 98 % of the ferritin in the CSF come from the CNS. |
Accredited | ja |
More Results for the letter F
- Factor II activity (FACT01)
- Prothrombin
- Factor II mutation (FACT02)
- Prothrombin mutation G20210A
- Factor IX activity (FACT11)
- Factor V activity (FACT03)
- Factor V mutation Leiden (FACT04)
- Mutation: G1691A
- Factor VII activity (FACT05)
- Factor VIII activity (FACT06)
- Factor VIII inhibitor (FACT10)
- Factor VIII ristocetin cofactor (von Willebrand factor activity) (FACT08)
- vWF:activity
- Factor VIII von Willebrand factor antigen (FACT07)
- vWF:Ag
- Factor VIII von Willebrand multimers (FACT09)
- Factor X activity (FACT12)
- Factor XI activity (FACT13)
- Factor XII activity (FACT14)
- Hageman-Factor
- Factor XIII activity (FACT15)
- Syn.: fibrin stabilising factor
- Factor–II–activity (FAK2)
- Prothrombin
- Factor-II-mutation (FAK2GM)
- Prothrombin mutation G20210A
- Factor-IX-activity (FAK9)
- Factor-V-activity (FAK5)
- Factor-V-mutation Leiden (FAK5GM)
- Mutation: G1691A
- Factor-VII-activity (FAK7)
- Factor-VIII-activity (FAK8)
- Factor-VIII-inhibitor (FAK8IN)
- Bethesda assay
- Factor-X-activity (FAK10)
- Factor-XI-activity (FAK11)
- Factor-XII-activity (FAK12)
- Hageman factor
- Factor-XIII-activity (FAK13)
- Fibrin-stabilizing factor
- Fasciola hepatica (FASCI, FASCG)
- Common liver fluke
- Fat, total in stool (FETT1)
- Fatty acids, long-chained (LAFS)
- LCFA